A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05469737 |
Recruitment Status :
Recruiting
First Posted : July 22, 2022
Last Update Posted : April 9, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Myelodysplastic Syndromes | Drug: Oral Azacitidine Drug: Placebo for Oral Azacitidine | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 230 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) |
Actual Study Start Date : | December 14, 2022 |
Estimated Primary Completion Date : | January 31, 2026 |
Estimated Study Completion Date : | July 29, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Part I - Oral-Aza (Dose 1) |
Drug: Oral Azacitidine
Specified dose on specified days
Other Names:
|
Experimental: Part I - Oral-Aza (Dose 2) |
Drug: Oral Azacitidine
Specified dose on specified days
Other Names:
|
Experimental: Part II - Oral-Aza (RP3D)
RP3D: Recommended Phase 3 Dose
|
Drug: Oral Azacitidine
Specified dose on specified days
Other Names:
|
Experimental: Part II - Placebo |
Drug: Placebo for Oral Azacitidine
Specified dose on specified days |
- Number of participants with Adverse Events (AEs) evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) criteria v.5.0 [ Time Frame: 6 cycles plus 28 days (up to 24 weeks) ]Phase 2
- Number of participants who achieved complete remission (CR) per International Working Group (IWG) 2006 criteria within 6 cycles [ Time Frame: Up to 24 weeks ]Phase 2 and 3
- Number of participants who achieved Overall Response (OR) per IWG 2006 criteria within 6 cycles [ Time Frame: Up to 24 weeks ]
Phase 2 and Phase 3
Overall Response is defined as complete response (CR), partial remission (PR), marrow complete response (mCR), hematologic improvement-erythroid response (HI-E), hematologic improvement-platelet response (HI-P), or hematologic improvement-neutrophil response (HI-N) as per IWG 2006 criteria
- Number of participants who achieved 84-day packed red blood cells transfusion independence (pRBC-TI) [ Time Frame: Up to 32 weeks ]Phase 2 and Phase 3
- pRBC-TI duration [ Time Frame: Over the course of the study, an average of 1 year ]Phase 2 and Phase 3
- Number of participants who achieve 84 day platelet transfusion independence (PLT-TI) within 6 cycles [ Time Frame: Over the course of the study, an average of 1 year ]Phase 2 and Phase 3
- PLT-TI duration [ Time Frame: Over the course of the study, an average of 1 year ]Phase 2 and Phase 3
- Number of participants who achieved pRBC transfusion reduction [ Time Frame: Over the course of the study, an average of 1 year ]Phase 3
- pRBC transfusion reduction duration [ Time Frame: Over the course of the study, an average of 1 year ]Phase 3
- CR duration [ Time Frame: Over the course of the study, an average of 1 year ]Phase 2 and Phase 3
- Best OR [ Time Frame: Over the course of the study, an average of 1 year ]Phase 2 and Phase 3
- OR duration [ Time Frame: Over the course of the study, an average of 1 year ]Phase 2 and Phase 3
- Overall Survival (OS) [ Time Frame: Up to 5 years after discontinuation of Investigational Product, approximately 6 years ]Phase 3
- Event-free Survival (EFS) [ Time Frame: Up to 5 years after discontinuation of Investigational Product, approximately 6 years ]Phase 3
- Time to acute myeloid leukemia (AML) [ Time Frame: Up to 5 years after discontinuation of Investigational Product, approximately 6 years ]Phase 3
- Time to subsequent therapy [ Time Frame: Up to 5 years after discontinuation of Investigational Product, approximately 6 years ]Phase 3
- Iron parameters measured from blood [ Time Frame: Over the course of the study, an average of 1 year ]Phase 3
- Number of participants with Adverse Events (AEs) evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) criteria v.5.0 [ Time Frame: Up to end of treatment/early termination, an average of 1 year ]Phase 3
- Summary statistics for Functional Assessment of Cancer Therapy-Anemia (FACT-An) scales and subscales at each assessment point for each treatment arm [ Time Frame: Up to end of treatment/early termination, an average of 1 year ]Phase 3
- Summary statistics for Quality of Life in Myelodysplasia Scale (QUALMS) scales and subscales at each assessment point for each treatment arm [ Time Frame: Up to end of treatment/early termination, an average of 1 year ]Phase 3
- Summary statistics for the EuroQol 5 Dimension 5 Level (EQ-5D-5L) scales and subscales at each assessment point for each treatment arm [ Time Frame: Up to end of treatment/early termination, an average of 1 year ]Phase 3
- Number of participants with healthcare resource use associated with the investigational product (IP) [ Time Frame: Over the course of the study, an average of 1 year ]Phase 3
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
• Participant has a documented diagnosis of MDS according to WHO 2016 classification that meets International Prognostic Scoring System Revised (IPSS-R) classification of low- or intermediate-risk disease (IPSS-R score between 1.5 and 4.5).
MDS diagnosis, WHO classification, and IPSS-R risk classification will be prospectively determined by independent central pathology and cytogenetics review, and applicable central laboratory results.
• Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
Exclusion Criteria:
- Participants with prior malignancies must have an expected median life expectancy of at least 12 months at the time of inclusion and no active treatment of any sort for at least 24 weeks prior to randomization (including but not limited to immunotherapy or targeted therapy)
- Hypoplastic Myelodysplastic Syndrome (MDS) with a marrow cellularity of ≤ 10%
- Participants diagnosed with MDS with excess blasts-2 (MDS-EB2)
- Prior treatment with azacitidine (any formulation), decitabine, or other hypomethylating agent
Other protocol-defined inclusion/exclusion criteria apply
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05469737
Contact: BMS Study Connect Contact Center http://www.bmsstudyconnect.com | 855-907-3286 | Clinical.Trials@bms.com | |
Contact: First line of the email MUST contain NCT # and Site #. |
Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
Responsible Party: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT05469737 |
Other Study ID Numbers: |
CA055-026 U1111-1276-5463 ( Other Grant/Funding Number: WHO ) |
First Posted: | July 22, 2022 Key Record Dates |
Last Update Posted: | April 9, 2024 |
Last Verified: | April 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Anemia Thrombocytopenia |
Preleukemia Myelodysplastic Syndromes Syndrome Disease Pathologic Processes Bone Marrow Diseases Hematologic Diseases Precancerous Conditions |
Neoplasms Azacitidine Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Enzyme Inhibitors |